Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: Acute comparison and differential response

American Journal of Psychiatry

Volumn 165, Issue 6, 2008, Pages 721-730

  Newcorn, Jeffrey H ^a   Kratochvil, Christopher J ^b   Allen, Albert J ^b   Casat, Charles D ^b   Ruff, Dustin D ^b   Moore, Rodney J ^b   Michelson, David ^b   Bailey, Charles E ^b   Dunn, David W ^b   Frank, L Matthew ^b   Gutierrez, Rosben L ^b   Jain, Rakesh ^b   Lehman, Robert B ^b   Londborg, Peter D ^b   Melmed, Raun ^b   Quintana, Humberto ^b   Sangal, R Bart ^b   Robinson, Shannon K ^b   Sarkis, Elias H ^b   Saylor, Keith E ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; PLACEBO;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DECREASED APPETITE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; FEMALE; HEART RATE; HUMAN; INSOMNIA; IRRITABILITY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NAUSEA; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; VITAL SIGN; VOMITING; WEIGHT CHANGE; WEIGHT REDUCTION;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PERSONALITY ASSESSMENT; PROPYLAMINES; TREATMENT OUTCOME;

EID: 44949116355     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.2007.05091676     Document Type: Article

References (29)

1. Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ: Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004; 114(1):e1-e8
2. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T, Atomoxetine ADHD Study Group: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108(5):e83
3. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D: Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002; 159:1896-1901
4. Spencer TJ, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ: Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002; 63:1140-1147
5. Jadad AR, Boyle M, Cunningham C, Kim M, Schachar R: Evidence Report/Technology Assessment number 11: Treatment of Attention-Deficit/ Hyperactivity Disorder (AHCPR Publication 99-E018). Rockville, Md, Agency for Healthcare Research and Quality, 1999
6. Kratochvil CJ, Heiligenstein JH, Dittmann R, Spencer T, Biederman J, Wernicke JF, Newcorn J, Casat C, Milton D, Michelson D: Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002; 41:776-784
7. Sangal RB, Owens J, Allen AJ, Sutton V, Schuh K, Kelsey D: Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep 2006; 29:1573-1585
8. Kemner JE, Starr HL, Ciccone PE, Hooper-Wood CG, Crockett RS: Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Ther 2005; 22:498-512
9. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R: ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York, Guilford, 1998
10. Wigal SB, McGough JJ, McCracken JT, Biederman J, Spencer TJ, Posner KL, Wigal TL, Kollins SH, Clark TM, Mays DA, Zhang Y, Tulloch SJ: A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 2005; 9:275-289
11. Pliszka S; AACAP Work Group on Quality Issues: Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:894-921
12. American Academy of Pediatrics: Treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108:1033-1043
13. MTA Cooperative Group: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999; 56:1073-1086
14. Kaufman J, Birmaher B, Brent D, Rao U, Ryan N: Schedule for Affective Disorders and Schizophrenia for School Aged Children - Present and Lifetime Version (K-SADS-PL). Pittsburgh, University of Pittsburgh Press, 1996
15. World Medical Association: Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Ferney-Voltaire, France, World Medical Association, 2000 (http://www.wma.net/e/policy/b3.htm)
16. Gao H, Zhao Y, Levine L, Allen A: Determining cut-points for clinically meaningful improvement: a receiver operating characteristic approach, in Scientific Proceedings of the 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Washington, DC, American Academy of Child and Adolescent Psychiatry, 2006, p 201
17. Sangal RB, Sangal JM: Attention-deficit/hyperactivity disorder: use of cognitive evoked potential (P300) to predict treatment response. Clin Neurophysiol 2006; 117:1996-2006
18. Spencer TJ, Adler LA, McGough JJ, Muniz R, Jiang H, Pestreich L, Adult ADHD Research Group: Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2007; 61:1380-1387
19. Conners CK: Conners' Rating Scales: Revised Technical Manual. North Tonawanda, NY, Multi-Health Systems, 1997
20. Landgraf JM, Abetz L, Ware JE: The CHQ User's Manual, 1st ed. Boston, Tufts-New England Medical Center, Health Institute, 1996
21. Physician's Desk Reference. Montvale, NJ, Thomson Healthcare, 2005
22. Spencer T, Biederman J, Heiligenstein J, Wilens T, Faries D, Prince J, Faraone SV, Rea J, Witcher J, Zervas S: An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001; 11:251-265
23. International Conference on Harmonization: ICH Harmonized Tripartite Guideline: Statistical Principles for Clinical Trials (E9). Fed Regist 1998; 63(179):49583
24. Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM: Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2006; 160:82-90
25. Biederman J, Faraone S, Monuteaux MC, Grossbard JR: How informative are parent reports of attention-deficit/hyperactivity disorder symptoms for assessing outcome in clinical trials of long-acting treatments? A pooled analysis of parents' and teachers' reports. Pediatrics 2004; 113:1667-1671
26. Bohnstedt BN, Kronenberger WG, Dunn DW, Giauque AL, Wood EA, Rembusch ME, Lafata D: Investigator ratings of ADHD symptoms during a randomized, placebo-controlled trial of atomoxetine: a comparison of parents and teachers as informants. J Atten Disord 2005; 8:153-159
27. Faraone SV, Biederman J, Roe C: Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. J Clin Psychopharmacol 2002; 22:468-473
28. Newcorn JH, Zhang S, Sutton V, Feldman P, Sumner C, Michelson D, Findling R, Davidson PA, Figge K: Differential response to stimulants and atomoxetine, in Scientific Proceedings of the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Washington, DC, American Academy of Child and Adolescent Psychiatry, 2004, p 48
29. US Food and Drug Administration: Suicidality in Children and Adolescents Being Treated With Antidepressant Medications. Washington, DC, FDA, Oct 15, 2004